News
KZR
--
0.00%
--
Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in the...
Business Wire · 02/25 21:01
What Kind Of Investors Own Most Of Kezar Life Sciences, Inc. (NASDAQ:KZR)?
The big shareholder groups in Kezar Life Sciences, Inc. ( NASDAQ:KZR ) have power over the company. Large companies...
Simply Wall St. · 02/16 05:53
Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
Business Wire · 02/10 21:01
Vox Notes Development Updates & Exploration Success From Operating Partners
Vox Notes Development Updates & Exploration Success From Operating Partners
CNW Group · 02/02 12:00
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporat...
Business Wire · 01/07 21:02
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporat...
Business Wire · 01/07 21:02
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Business Wire · 01/07 21:02
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporat...
BusinessWire · 01/07 18:02
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporat...
BusinessWire · 01/07 18:02
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Simply Wall St. · 12/18/2020 08:13
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 12/18/2020 08:13
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Simply Wall St. · 12/18/2020 08:13
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Benzinga · 12/15/2020 12:52
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Kezar Life Sciences (KZR) has been added to the NASDAQ Biotech Index, effective Dec. 21, 2020 before market open.In the past year, the stock has gained 103.7% vs. 23.8% gains
Seekingalpha · 12/14/2020 21:20
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Business Wire · 12/14/2020 21:01
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI)...
Business Wire · 12/14/2020 21:01
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI)...
Business Wire · 12/14/2020 21:01
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI)...
BusinessWire · 12/14/2020 18:01
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI)...
BusinessWire · 12/14/2020 18:01
Webull provides a variety of real-time KZR stock news. You can receive the latest news about Kezar Life Sciences through multiple platforms. This information may help you make smarter investment decisions.
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.